Kailera Therapeutics (NASDAQ:KLRA) Trading Up 8.6% – What’s Next?

Posted by Brian Himes on Aug 25th, 2026

Kailera Therapeutics, Inc. (NASDAQ:KLRA – Get Free Report)’s stock price shot up 8.6% on Tuesday . The company traded as high as $18.19 and last traded at $17.96. 757,067 shares changed hands during mid-day trading, an increase of 5% from the average daily volume of 717,646 shares. The stock had previously closed at $16.54.

Analyst Ratings Changes

Several research analysts recently commented on KLRA shares. Leerink Partners initiated coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating and a $36.00 price objective for the company. TD Cowen started coverage on shares of Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price target on the stock. William Blair started coverage on Kailera Therapeutics in a research report on Tuesday, May 12th. They set an “outperform” rating on the stock. Jefferies Financial Group initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $48.00 price objective for the company. Finally, Zacks Research upgraded Kailera Therapeutics to a “hold” rating in a research note on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Kailera Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $42.75.

Check Out Our Latest Research Report on KLRA

Kailera Therapeutics Price Performance

The firm’s 50-day moving average is $19.22. The company has a market capitalization of $2.31 billion and a PE ratio of -0.00.

Kailera Therapeutics (NASDAQ:KLRA – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($1.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.35). As a group, equities research analysts predict that Kailera Therapeutics, Inc. will post -3.89 earnings per share for the current fiscal year.

Institutional Trading of Kailera Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in KLRA. California State Teachers Retirement System purchased a new position in shares of Kailera Therapeutics during the second quarter worth $309,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Kailera Therapeutics during the 2nd quarter valued at about $24,233,000. Atlas Venture Life Science Advisors LLC purchased a new position in shares of Kailera Therapeutics during the 2nd quarter valued at about $113,923,000. Finally, Wellington Management Group LLP acquired a new position in shares of Kailera Therapeutics in the 2nd quarter valued at about $64,308,000.

Kailera Therapeutics Company Profile

(Get Free Report)

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.